Working... Menu
Trial record 1 of 1 for:    MET44
Previous Study | Return to List | Next Study

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01732627
Recruitment Status : Completed
First Posted : November 26, 2012
Last Update Posted : February 9, 2018
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )

Brief Summary:

Primary objectives:

  • To describe the antibody responses to meningococcal serogroups A, C, Y, and W-135, measured by serum bactericidal assay using human complement (hSBA) and baby rabbit complement (SBA-BR), induced by a single dose of MenACYW conjugate vaccine or Menomune® - A/C/Y/W-135.
  • To describe the safety profile of a single dose of MenACYW conjugate vaccine or Menomune® - A/C/Y/W-135.

Condition or disease Intervention/treatment Phase
Meningitis Meningococcal Meningitis Meningococcal Infections Invasive Meningococcal Disease Biological: MenACYW Conjugate Vaccine Biological: Meningococcal Polysaccharide Vaccine Groups A, C, Y, W 135 Combined Phase 2

Detailed Description:
All participants will receive a single dose of their assigned vaccine on Day 0. They will be assessed for immunogenicity on Day 30, and monitored for safety throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Subjects 56 Years of Age and Older
Study Start Date : November 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : September 2013

Arm Intervention/treatment
Experimental: MenACYW Vaccine Group
Participants who receive MenACYW conjugate vaccine
Biological: MenACYW Conjugate Vaccine
0.5 mL, Intramuscular

Active Comparator: Menomune® A/C/Y/W 135 Vaccine Group
Participants will receive Menomune® A/C/Y/W 135 Vaccine
Biological: Meningococcal Polysaccharide Vaccine Groups A, C, Y, W 135 Combined
0.5 mL, Subcutaneous
Other Name: Menomune® A/C/Y/W 135

Primary Outcome Measures :
  1. Percentages of Participants with Seroresponse in terms of functional antibodies to the meningococcal serogroups after Vaccination with either MenACYW conjugate or Menomune® Vaccine [ Time Frame: Day 30 post-vaccination ]
    Immunogenicity endpoints on serum bactericidal antibody titers for each meningococcal serogroup will be measured by serum bactericidal assay using human and rabbit complements

  2. Number of Participants Reporting Solicited Injection Site Reactions, Solicited Systemic Reactions, Unsolicited Systemic Reactions, and Serious Adverse Events Occurring after vaccination with either MenACYW conjugate or Menomune® Vaccine [ Time Frame: Day 0 up to Day 30 post vaccination. ]
    Solicited injection site reactions: pain, erythema, and swelling. Solicited systemic reactions: fever (temperature), headache, malaise, and myalgia.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   56 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Aged 56 or older on the day of inclusion
  • Informed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria:
  • Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)
  • Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
  • Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine in the 4 weeks following the trial vaccination except for influenza vaccination, which may be received at least 2 weeks before or after the study vaccines
  • Previous vaccination against meningococcal disease with either a trial vaccine or another vaccine
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically
  • At high risk for meningococcal infection during the trial
  • Known systemic hypersensitivity to latex or any of the vaccine components, or history of a severe reaction to the vaccines used in the trial or to a vaccine containing any of the same substances
  • Personal history of Guillain-Barré syndrome
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within at least 10 years of the proposed study vaccination
  • Self-reported thrombocytopenia, contraindicating intramuscular vaccination
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  • Current alcohol abuse or drug addiction
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 100.4°F [≥ 38.0°C]). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided
  • Receipt of oral or injectable antibiotic therapy within 3 days prior to any blood draw. Should a subject receive oral or injectable antibiotic therapy within 3 days prior to any blood draw, the Investigator will postpone the blood draw until it has been 3 days since the subject last received oral or injectable antibiotic therapy. Postponement must still be within the timeframe for blood draw indicated in the Table of Study Procedures, when possible
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01732627

Layout table for location information
United States, Arizona
Chandler, Arizona, United States, 85224
Scottsdale, Arizona, United States, 85251
United States, Colorado
Denver, Colorado, United States, 80239
United States, Connecticut
Milford, Connecticut, United States, 06460
United States, Minnesota
Edina, Minnesota, United States, 55435
United States, Missouri
Saint Louis, Missouri, United States, 63141
United States, Ohio
Columbus, Ohio, United States, 43212
United States, South Carolina
Anderson, South Carolina, United States, 29621
United States, Utah
Murray, Utah, United States, 84123
Salt Lake City, Utah, United States, 84124
West Jordan, Utah, United States, 84088
United States, Virginia
Charlottesville, Virginia, United States, 22911
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
Layout table for investigator information
Study Director: Medical Director Sanofi Pasteur Inc.

Additional Information:
Layout table for additonal information
Responsible Party: Sanofi Pasteur, a Sanofi Company Identifier: NCT01732627     History of Changes
Other Study ID Numbers: MET44
U1111-1127-6804 ( Other Identifier: WHO )
First Posted: November 26, 2012    Key Record Dates
Last Update Posted: February 9, 2018
Last Verified: February 2018

Keywords provided by Sanofi ( Sanofi Pasteur, a Sanofi Company ):
Meningococcal Meningitis
Menomune® A/C/Y/W-135

Additional relevant MeSH terms:
Layout table for MeSH terms
Meningococcal Infections
Meningitis, Meningococcal
Central Nervous System Diseases
Nervous System Diseases
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Meningitis, Bacterial
Central Nervous System Bacterial Infections
Central Nervous System Infections
Immunologic Factors
Physiological Effects of Drugs